Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
5
SFDA:3
FDA:2
Drug Approvals
Clinical Trials
No trials found
News
Cycle Pharmaceuticals Secures Exclusive U.S. Rights to PHYRAGO, Novel Dasatinib Formulation for Leukemia Treatment
Cycle Pharmaceuticals has entered an exclusive U.S. commercialization agreement with Handa Therapeutics for PHYRAGO, an FDA-approved dasatinib formulation for treating Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
FDA Approves First Treatment for Alkaptonuria: Nitisinone Shows Clinical Benefits in Rare Metabolic Disorder
The FDA approved nitisinone (Harliku) as the first and only treatment for alkaptonuria, a rare genetic metabolic disorder affecting 1 in 250,000 to 1 million Americans.
Cycle Pharmaceuticals Launches VENXXIVA for Cystinuria Treatment in the US
Cycle Pharmaceuticals has launched VENXXIVA (tiopronin) Delayed-Release Tablets for treating cystinuria in the US, partnering with Torrent Pharma and Vanscoy Rare Pharmacy for distribution.